First-line therapy for impacting kidney cancer, immunocombination therapy significantly prolongs PFS
February 09, 2018 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Recently, Roche's subsidiary Genentech announced that its combination of PD-L1 inhibitor Tecentriq and Avastin (Avastin, bevacizumab) for patients with advanced or metastatic renal cell carcinoma (mRCC) For obvious benefit, these patients have not received systemic or experimental therapies.
According to the American Cancer Society, more than 63,300 people will be diagnosed with kidney cancer in 2018. About 90% of kidney cancers are renal cell carcinoma (RCC). RCC usually occurs in small tubes (also known as renal tubules) that filter blood. Typically, RCC is a single tumor in one kidney, but in rare cases there may be multiple tumors, which may occur in one or two kidneys. Despite recent advances in the field of kidney cancer, treatment options for patients with this disease are still limited.
Tecentriq is the first FDA-approved PD-L1 antibody drug for the treatment of certain types of advanced urothelial carcinoma (including bladder cancer) and non-small cell lung cancer. Tecentriq is a monoclonal antibody that binds to PD-L1 protein expressed on tumor cells and tumor-infiltrating immune cells, blocking its interaction with PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq can reactivate T cells. Genentech has currently conducted 17 Phase III clinical studies related to Tecentriq in different cancers. Genentech believes that the combination of vascular endothelial growth factor (VEGF) and the intravenous bioassay Avastin can increase Tecentriq's ability to restore the body's anti-cancer immunity. The rationale is that this combination promotes tumor infiltration of T cells and is capable of eliciting and activating T cell responses against tumor antigens.
Genentech said that combination therapy can improve progression-free survival in patients with mRCC expressing PD-L1 by 26% in phase 3 clinical trials. In this phase 3 clinical trial, Genentech tested the efficacy of the Tecentriq/Avastin combination therapy in contrast to standard therapies. The results of the trial showed that the combination therapy "significantly delayed (the time of mRCC symptoms worsening)", deterioration will affect daily life. The mean median time to deterioration of combination therapy was 11.3 months, compared with 4.3 months for standard therapy.
The late-stage clinical study, IMmotion 151, involved 915 patients, evaluating the potential of this combination therapy as a first-line therapy for mRCC and reaching a common primary endpoint for progression-free survival. Patients receiving combination therapy had a 26% lower risk of disease progression or death compared with the standard treatment group (PFS). Genentech revealed that the progression-free survival of the experimental group was 11.2 months, compared with 7.7 months in the control group. The overall survival of the other primary endpoint has not yet been reached. Genentech said the data is encouraging, but has not yet reached a final conclusion.
Dr. Sandra Horning, chief medical officer and head of global product development at Genentech, pointed out that the latest phase 3 data is the second phase 3 clinical study with positive results from Tecentriq and Avastin. In December, Genentech announced that Tecentriq/Avastin combination therapy reduced the risk of disease progression or death in previously untreated advanced non-squamous non-small cell lung cancer (NSCLC) by 38%.
Dr. Horning said: "Tecentriq and Avastin as initial treatments can significantly reduce the risk of disease progression or death in patients with advanced kidney cancer, and can provide patients with more time than standard therapy, delaying disease progression to interfere with daily life, we This is exciting. We look forward to discussing these results with global regulators."
Genentech said it will present data on the IMmotion 151 trial at the 2018 urogenital cancer workshop on February 10.
We hope that this combination therapy will be approved soon to improve the quality of life of patients with kidney cancer.
Reference materials:
[1] Genentech's Tecentriq Impresses Again in Late-Stage Kidney Cancer Trial
[2] Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death by 26 Percent in Certain People with Advanced Kidney Cancer
[3] Genentch official website
High Frequency Electrosurgical Generator
High frequency Electrosurgical Generator
ZHEJIANG SHENDASIAO MEDICAL INSTRUMENT CO.,LTD. , https://www.sdsmedtools.com